Clinical Trials Logo

Clinical Trial Summary

This project is an open, dose escalation and expansion phase I clinical study. The first phase is a dose escalation study, and the second phase is a dose expansion study based on the Maximum tolerated dose (MTD) / Recommended Phase II Dose (RP2D) obtained in the first phase. The purpose is to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQB2916 injection in patients with advanced tumors, and to initially evaluate the antitumor efficacy of TQB2916 injection.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05213767
Study type Interventional
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact Yi Ba, Doctor
Phone 18622221230
Email bayi@tjmuch.com
Status Not yet recruiting
Phase Phase 1
Start date February 2022
Completion date July 2023

See also
  Status Clinical Trial Phase
Recruiting NCT06245122 - A Study of CS23546 in Subjects With Advanced Tumors Phase 1
Not yet recruiting NCT06314087 - iTAPVR Study - Phase II Randomized Study Phase 2
Recruiting NCT05390528 - A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma Phase 1/Phase 2
Completed NCT02419417 - Study of BMS-986158 in Subjects With Select Advanced Cancers Phase 1/Phase 2
Completed NCT04808453 - Phase I Study of CPI-300 in Patients With Advanced Tumors Phase 1
Recruiting NCT05799183 - A SHR-1210 BE Study on Healthy Subjects Phase 1
Recruiting NCT05429008 - A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm Phase 1
Terminated NCT04198818 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors Phase 1/Phase 2
Not yet recruiting NCT04151810 - Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05068856 - A Study of HRS2543 in Patients With Advanced Tumors Phase 1
Completed NCT03781362 - Study of CPI-100 in Patients With Advanced Tumors Phase 1
Recruiting NCT03908814 - Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors Phase 1
Recruiting NCT05061628 - The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor Phase 1
Recruiting NCT05867771 - A Study of PM1022 in Patients With Advanced Tumors Phase 1/Phase 2
Recruiting NCT03444714 - Phase I Study of RiMO-301 With Radiation in Advanced Tumors Phase 1